<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01492621</url>
  </required_header>
  <id_info>
    <org_study_id>DTI</org_study_id>
    <nct_id>NCT01492621</nct_id>
  </id_info>
  <brief_title>Effect of Antidepressants on White Matter Structure</brief_title>
  <official_title>White Matter Structure and Response to Treatment With Antidepressants: a Study of Desvenlafaxine in Major Depression. A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de recherche Fernand-Seguin, Hôpital Louis-H. Lafontaine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects with major depression will be evaluated and intensively characterized through
      questionnaires, computerized cognitive evaluation and laboratory investigations. Magnetic
      resonance imaging will be used to document baseline white matter structure. subjects will
      then receive desvenlafaxine which will be adjusted as clinically indicated. After 16 weeks
      the evaluations will be repeated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      40 subjects will be included in the study. Diagnosis will be confirmed by MINI. Participants
      will be characterised using questionnaires, pain threshold, cognition, facial expression
      recording and MRI. Desvenlafaxine will be initiated at 50mg AM. At week 8 Desvenlafaxine may
      be increased to 100mg as clinically indicated. Measures will be repeated at the end of the
      study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">November 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anisotropy</measure>
    <time_frame>16 weeks</time_frame>
    <description>Degree of anisotropy will be measured at baseline and 16 weeks and correlated to remission status</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cognitive measures</measure>
    <time_frame>16 weeks</time_frame>
    <description>cognitive deficits will be measured at baseline and 16 weeks and correlated to anisotropy using computerized neuropsychological testing of memory, speed and executive function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain threshold</measure>
    <time_frame>16 weeks</time_frame>
    <description>Pain threshold will be measured at basline and 16 weeks and correlated to inflammatory markers and anisotropy</description>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Major Depression</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desvenlafaxine</intervention_name>
    <description>Desvenlafaxine 50mg from week 1-8. At week 8 optional increase to 100mg if remission has not been attained.</description>
    <other_name>Pristiq</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Major depression

          -  Age 18 to 55

          -  Hamilton grater or equal to 20

        Exclusion Criteria:

          -  Major neurologic disorder

          -  Major cardiovascular disorder

          -  Unstable medical condition

          -  Significant psychiatric co-morbidity

          -  Current substance dependance

          -  Pregnancy or lactation -Treatment resistance as defined by nonresponse to 2 or more
             antidepressant treatments (adequate dose and duration) -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Smadar V Tourjman, MDCM</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Montreal, Centre de recherche Fernand Seguin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>souad Lahlafi, BNurs</last_name>
    <phone>5142514000</phone>
    <phone_ext>3416</phone_ext>
    <email>slahlafi.crfs@ssss.gouv.qc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Louise Normandeau, Nurs</last_name>
    <phone>5142514000</phone>
    <phone_ext>3535</phone_ext>
    <email>lnormandeau.hlhl@ssss.gouv.qc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre de Recherche Fernand-Seguin</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1N3V2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Souad Lahlafi, Bnurs</last_name>
      <phone>5142514000</phone>
      <phone_ext>3416</phone_ext>
      <email>slahlafi.crfs@ssss.gouv.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Louise Normandeau, Nurs</last_name>
      <phone>5142514000</phone>
      <phone_ext>3535</phone_ext>
      <email>lnormandeau.hlhl@ssss.gouv.qc.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2011</study_first_submitted>
  <study_first_submitted_qc>December 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2011</study_first_posted>
  <last_update_submitted>December 14, 2011</last_update_submitted>
  <last_update_submitted_qc>December 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre de recherche Fernand-Seguin, Hôpital Louis-H. Lafontaine</investigator_affiliation>
    <investigator_full_name>Valerie Tourjman</investigator_full_name>
    <investigator_title>Associate director of clinical research</investigator_title>
  </responsible_party>
  <keyword>major depression</keyword>
  <keyword>DTI</keyword>
  <keyword>inflammatory markers</keyword>
  <keyword>cognition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Desvenlafaxine Succinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

